Tirzepatide exists under two brand names: Mounjaro and Zepbound. Both are manufactured by Eli Lilly, both contain identical active ingredient at identical doses, and both work through the same GLP-1/GIP dual mechanism. The only structural difference is the FDA approval each carries — and that difference has enormous practical consequences for coverage and cost.
The dose structure (same for both)
Both Mounjaro and Zepbound are available in the following weekly injection doses:
- 2.5 mg (starting/titration dose)
- 5 mg
- 7.5 mg
- 10 mg
- 12.5 mg
- 15 mg (maximum dose)
The titration protocol — starting at 2.5 mg and increasing every four weeks as tolerated — is the same regardless of which brand name is on the box.
Mounjaro: the diabetes label
Mounjaro was approved in May 2022 for type 2 diabetes management. If you have type 2 diabetes, this is the on-label product. Plans that cover tirzepatide for diabetes will reference Mounjaro specifically. The Lilly savings card for Mounjaro can reduce copays for eligible commercially insured patients.
Zepbound: the weight management label
Zepbound was approved in November 2023 for chronic weight management. If you do not have diabetes, this is the correct on-label product for obesity treatment. Coverage varies significantly — some commercial plans include it, others exclude it or require prior authorisation. Medicare's coverage of Zepbound as a weight-management drug has been limited under traditional Part D rules.
Which brand to ask for — a simple decision tree
- You have type 2 diabetes and your plan covers Mounjaro → Ask for Mounjaro. It is on-label, covered, and identical to Zepbound.
- You have obesity without diabetes and your plan covers Zepbound → Ask for Zepbound. It is the correct on-label product.
- Your plan covers neither → Compounded tirzepatide through a reputable telehealth provider is the most accessible cash-pay option. The active molecule is the same.
- You have both diabetes and obesity → Discuss with your prescriber which label gives you better access under your specific plan.
What happens if you get the wrong brand
If your plan covers Mounjaro for diabetes and your prescriber writes Zepbound for weight management, your claim will likely be denied. The reverse is also true. Since the drugs are pharmacologically identical, this is frustrating — but it is how the US coverage system works. Getting the brand name right on the prescription matters.
This content is educational. Work with your prescriber and insurer to confirm which brand is covered under your specific plan before filling a prescription.
About the author
Modern Weight Science Editorial Team
Editorial Team
Evidence-based research and educational content focused on metabolism, appetite regulation, and sustainable weight management. Our team synthesizes peer-reviewed research into clear, accessible guidance for informed health decisions.
Every claim is checked against peer-reviewed research through our review process and fact-checking policy.
Frequently Asked Questions
What is the difference between Ozempic and Wegovy?
Both contain semaglutide, but they are FDA-approved for different indications. Ozempic (up to 2mg) is approved for type 2 diabetes management and cardiovascular risk reduction. Wegovy (up to 2.4mg) is approved for chronic weight management. The distinction directly affects insurance coverage, maximum dose, and prescribing eligibility — and the two are not interchangeable through most pharmacies.
Do I need a prescription for semaglutide or tirzepatide?
Yes. Semaglutide and tirzepatide are prescription-only medications in the United States and most countries. They require evaluation and a prescription from a licensed healthcare provider. Compounded versions have been available through telehealth platforms, but these are not FDA-approved and carry different regulatory and quality considerations.
How long does it take to see results on GLP-1 medications?
Appetite changes are typically noticed in weeks 1-2. Meaningful weight loss (5-10% of body weight) generally occurs by weeks 12-20. Clinical trial results are measured at 68-72 weeks. The dose escalation schedule means the first 16-20 weeks are primarily about building tolerance, not maximum efficacy. Individual response varies significantly.
What happens when you stop taking a GLP-1 medication?
Most people regain a significant portion of lost weight within 12 months of stopping. Discontinuation studies show that the compensatory hunger and metabolic changes that GLP-1 medications suppress tend to return when the medication is withdrawn. Many clinicians now frame these as long-term treatments — similar to antihypertensives — rather than short-term interventions.
Continue learning
Where to read next
Not medical advice. This guide is for general education only. GLP-1 medications, dosing, and treatment suitability are decisions for you and a licensed clinician who knows your full medical history.